Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. reports developments as a clinical-stage biopharmaceutical company developing medicines for serious infectious diseases and cancer. Recurring updates cover its chronic hepatitis delta program, including the investigational combination of tobevibart and elebsiran, and its oncology portfolio of PRO-XTEN® dual-masked T-cell engagers across solid tumor targets.
Company news also includes clinical data presentations, trial progress, financial results, equity financing activity, and strategic collaborations. Its VIR-5500 program is a PSMA-targeted PRO-XTEN® dual-masked T-cell engager for metastatic prostate cancer, and the company also describes preclinical work across infectious diseases and oncologic malignancies.
Vir Biotechnology (NASDAQ: VIR) granted Norgine an exclusive commercial license for the combination of tobevibart + elebsiran to treat chronic hepatitis delta in Europe, Australia and New Zealand.
Key terms: an initial reimbursement payment of EUR 55 million, up to EUR 495 million in milestones, tiered mid‑teen to high‑twenties percent royalties, and shared ECLIPSE program costs with Norgine funding ~25% of go‑forward external costs. Vir retains U.S. and other non‑Greater China rights.
Corporate and clinical updates: ECLIPSE 3 enrollment completed; Vir expects existing cash, cash equivalents and investments to extend into Q4 2027 under the current plan. Prior Phase 2 SOLSTICE data showed 66% (21/32) achieved HDV RNA target not detected with the combination and no grade 3+ treatment‑related adverse events.
Vir Biotechnology (Nasdaq: VIR) announced that CEO Marianne De Backer will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 10:50 a.m. ET / 7:50 a.m. PT in Miami, Florida.
A live webcast will be available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.
Vir Biotechnology (Nasdaq: VIR) reported Week 48 Phase 2 SOLSTICE results showing the monthly combination of tobevibart + elebsiran achieved 66% HDV RNA target not detected (21/32) and ~90% HBsAg <10 IU/mL. ALT normalized in 56% at Week 48. The regimen was well tolerated with no grade 3+ treatment-related adverse events and no treatment-related discontinuations. Data were presented at AASLD The Liver Meeting® and published in the New England Journal of Medicine. Vir’s registrational ECLIPSE program is underway with topline results from ECLIPSE 1–3 expected in Q1 2027. The program holds FDA Breakthrough and Fast Track and EMA PRIME and orphan designations.
Vir Biotechnology (Nasdaq: VIR) announced that CEO Marianne De Backer will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18, 2025 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London.
A live webcast will be available via the company's Investors & Events page and the presentation will be archived online for 30 days.
Vir Biotechnology (NASDAQ: VIR) reported Q3 2025 results and a corporate update on November 5, 2025. The company ended the quarter with $810.7 million in cash, cash equivalents and investments and expects runway into mid-2027. Clinical highlights include ECLIPSE 1 enrollment completing ~two months ahead of schedule with primary completion expected in Q4 2026 and topline data for ECLIPSE 1–3 expected in Q1 2027. VIR-5500 first patient dosed in an ARPI combination study and a comprehensive VIR-5500 data update is planned for Q1 2026. Q3 financials: revenue $0.2M, R&D $151.5M, SG&A $22.2M, and net loss $163.1M ($1.17/share). A conference call was held November 5, 2025.
Vir Biotechnology (Nasdaq: VIR) announced completion of enrollment in ECLIPSE 1, a Phase 3 trial testing the combination of tobevibart + elebsiran for chronic hepatitis delta (CHD). The company said ECLIPSE 1's last patient is expected to reach the primary endpoint in Q4 2026, with topline data expected in Q1 2027. ECLIPSE 2 and 3 are enrolling and remain on track. The release notes high unmet medical need for CHD, no approved U.S. treatments, and regulatory designations including FDA Breakthrough Therapy and Fast Track and EMA PRIME and orphan drug for the combination.
Vir Biotechnology (Nasdaq: VIR) will provide a corporate update and report third quarter 2025 financial results on November 5, 2025.
The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on November 5, 2025. A press release with the corporate update and financial results will be issued shortly after market close and posted on the Investors > News page of Vir Biotechnology's website. A live webcast will be available via the Events & Presentations page; participants must register in advance to receive a unique access link. An archived replay will be available about two hours after the event and remain archived for 30 days.
Vir Biotechnology (Nasdaq: VIR) announced on October 9, 2025 that the first patient has been dosed in Part 3 of its Phase 1 trial evaluating VIR-5500 in combination with androgen receptor pathway inhibitors (ARPIs) for first-line pre-taxane metastatic castration-resistant prostate cancer (mCRPC).
VIR-5500 is a PRO-XTEN dual-masked T-cell engager targeting PSMA and is described as the only dual-masked PSMA-targeting TCE in clinical trials. The open-label, non-randomized study will assess safety, pharmacokinetics and preliminary anti-tumor activity. Earlier monotherapy data in heavily pre-treated mCRPC showed PSA reductions and a favorable safety profile during dose escalation.
Vir Biotechnology (NASDAQ: VIR) will present Week 48 endpoint results from the Phase 2 SOLSTICE study evaluating tobevibart (VIR-3434) alone and combined with elebsiran (VIR-2218) for chronic hepatitis delta at AASLD The Liver Meeting® 2025 in Washington, D.C., November 7-11.
Oral presentation: Week 48 SOLSTICE results on Nov 9, 2025 at 6:00 pm ET by Tarik Asselah, M.D., Ph.D. Poster: ECLIPSE registrational program design and objectives on Nov 8, 2025.
Vir Biotechnology (Nasdaq: VIR) announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference. CEO Marianne De Backer will engage in a fireside chat on September 9 at 1:05 p.m. PT / 4:05 p.m. ET in New York. Investors can access the live webcast through the company's website under the Events & Presentations section in the Investors area, with the recording remaining available for 30 days.